EANS-News: SYGNIS Pharma AG / Annual General Meeting of SYGNIS Pharma AG approves Combination of Businesses with X-Pol Biotech

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Annual & Special Corporate Meetings

Heidelberg (euro adhoc) - Annual General Meeting of SYGNIS Pharma AG
approves Combination of Businesses with X-Pol Biotech

* Comprehensive strategic realignment agreed * Election of new
Supervisory Board * Dr. Cristina Garmendia elected Chairwoman of the
Supervisory Board * Pilar de la Huerta will become the new CEO of
SYGNIS, Dr. Frank Rathgeb retires from the management board *
Revenues from DNA-amplification business projected to turn SYGNIS
profitable

Heidelberg, October 18, 2012 - SYGNIS Pharma AG (Frankfurt: LIOK;
ISIN DE000A1E9B74; Prime Standard) announced today that its
shareholders have approved significant strategic and personnel
changes of the company at yesterday's Annual General Meeting. These
changes are necessary following the suspended clinical development
activities in December 2011. Joining forces with X-Pol Biotech S.L.
ensures the continuation of the company, secures important expertise
and a sustainable business model.

SYGNIS' new business focus is to develop and market X-Pol's DNA
amplification technologies and products. The company's first
exclusive global license agreement was recently signed with Qiagen
and validated the X-Pol technology platform. The traditional
activities of SYGNIS in the capital intensive and risky drug
development sector are now replaced by a new core business with a
reliable revenue model. With this pragmatic orientation of the
business it is expected that first revenues will be realized in 2013.
In the medium term SYGNIS is aiming to develop a profitable business.

SYGNIS will acquire 100% ownership of X-Pol by way of a capital
increase against contribution in kind and therefore X-Pol will become
a 100% subsidiary of SYGNIS. The former shareholders of X-Pol hold
77.5% of SYGNIS shares. As part of these significant changes, the
Supervisory and Management Boards of SYGNIS have been aligned with
the new company strategy and shareholder structure.

SYGNIS shareholders have elected the new Supervisory Board, which
comprises: former Spanish Minister of Science, Dr. Cristina Garmendia
and Invitrogen founder Dr. Joseph M. Fernández, two internationally
recognized biotechnology experts. Additionally, successful
entrepreneurs Gonzalo Rodriguez-Fraile and Pedro Agustín del Castillo
were newly appointed to the Supervisory Board. Dr. Friedrich von
Bohlen und Halbach and Dr. Wolf-Dieter Starp, already members of the
Supervisory Board, have been re-appointed to the Board.

On a constituent meeting of the Supervisory Board following the AGM
Dr. Cristina Garmendia was elected as Chairwoman and Dr. Friedrich
von Bohlen as Deputy Chairman of the Supervisory Board. Furthermore,
the committee decided the appointment of Pilar de la Huerta, CEO of
GENETRIX, as CEO of SYGNIS. In a team together with Peter Willinger,
CFO of SYGNIS, she will implement the strategy, the operating plan
and the integration of both companies under the new SYGNIS
structures. Dr. Frank Rathgeb, the longtime Chief Medical Officer of
SYGNIS, who has played a significant role in the recent realignment
of SYGNIS, retires from the Management Board of SYGNIS on October 31,
2012 in mutual agreement with the Supervisory Board.

The new chairman of the Supervisory Board, Dr. Cristina Garmendia
said: "It is an honor to help shape this first merger between a
German and a Spanish company in the biotechnology industry, and it is
my ultimate goal to lead SYGNIS to success in the European and
international markets."

Dr. Friedrich von Bohlen, Deputy Chairman of the Supervisory Board,
added: "On behalf of the departing Supervisory Board I would like to
thank all those who have helped create this new joint beginning with
X-Pol. On behalf of the entire board, I especially want to thank all
the employees who have successfully promoted the programs of SYGNIS
in the past, even though clinical success unfortunately was denied in
the end. We also thank Dr. Frank Rathgeb for his untiring commitment
and many years of excellent work and wish him all the best for his
future. Furthermore, I would like to thank my board colleagues, Prof
Dr. Andrea Pfeifer, Prof. Dr. Christof Hettich, Prof. Dr. Werner
Hacke and Prof. Dr. Wolfgang Hartwig for their excellent cooperation,
often under difficult conditions. I know that they will retain their
close connections with the company."

The shareholders of SYGNIS agreed to all items of the agenda in the
AGM. At the AGM of SYGNIS 73% of the voting share capital was
represented.

For further information:

SYGNIS Pharma AG

Peter Willinger
CFO
SYGNIS Pharma AG

Tel.: +49 6221 454 836

E-mail: {peter.willinger@sygnis.de}[HYPERLINK:
mailto:peter.willinger@sygnis.de]

About SYGNIS Pharma AG: www.sygnis.de SYGNIS Pharma AG (Heidelberg,
Germany) is currently a specialty drug development company, focusing
on innovative treatments for underserved human diseases. Early in
2012 the company decided to discontinue its Phase II lead program
AX200 in stroke. While the company continued research activities in
the field of cognitive disorders, it started at the same time a
systematic M&A process, to add new operational assets and activities
to SYGNIS Pharma AG. SYGNIS Pharma AG is listed in the Prime Standard
of the Frankfurt Stock Exchange under the ticker: LIOK; and ISIN:
DE000A1E9B74.

About X-Pol Biotech, S.L.: www.xpolbiotech.com A biotechnology
company created by Prof. Luis Blanco and GENETRIX in 2008 with a
focus on the development of tools and technologies for the DNA
amplification and sequencing market. GENETRIX currently controls 84%
of the company. Other shareholders include renowned scientists,
Professor Luis Blanco and Professor Margarita Salas. "Qualiphi®" was
licensed with the Spanish National Research Council (CSIC) in 2010.

### Disclaimer This publication is intended for information only and
constitutes neither an offer to sell nor an invitation to buy
securities. Some statements included in this press release, relating
neither to proven financial results nor other historical data, should
be viewed as forward-looking, i.e. not definite. Such statements are
mainly predictions of future results, trends, plans or goals. These
statements should not be considered to be total guarantees since
given their very nature they are subject to known and unknown risks
and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not
undertake to publicly update or revise these statements in the light
of new information or future results or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English